<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211636</url>
  </required_header>
  <id_info>
    <org_study_id>SCIentinel-prolong</org_study_id>
    <nct_id>NCT04211636</nct_id>
  </id_info>
  <brief_title>Autoimmunity And Immune Deficiency After Spinal Cord Injury: Association With Rehabilitation Outcomes</brief_title>
  <official_title>Maladaptive Systemic Immune Response After Spinal Cord Injury: Humoral Post-traumatic Autoimmunity Against Central and Peripheral Nervous System Antigens in Association With Neurogenous Immune Depression as a Confounder of Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcel Kopp, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation Wings For Life</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unfallkrankenhaus Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Balgrist University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>I.R.C.C.S. Fondazione Santa Lucia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SCIentinel-prolong study systematically analyzes humoral autoantibody responses and thier&#xD;
      interaction with post-spinal cord injury (SCI) immune-deficiency and infections as well as&#xD;
      their association with the clinical course of rehabilitation. Therefore, molecular and&#xD;
      immunological tests in blood and cerebrospinal fluid specimen are combined with clinical&#xD;
      outcomes ranging from neurological function, neuropathic pain and spasticity to walking tests&#xD;
      and measures of independence in daily living within the first year after SCI. Including a&#xD;
      control group with participants suffering from vertebral fractures without SCI allows to&#xD;
      differentiate between neurological and general injury and treatment effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-traumatic autoimmunity</measure>
    <time_frame>3 months (10-14 weeks) post injury</time_frame>
    <description>Prevalence of autoantibodies against central and peripheral nervous system antigens in cerebrospinal fluid and serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Standards for Neurological Classification of SCI - Upper Extremity Motor Score</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Minimum 0, maximum 50; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Standards for Neurological Classification of SCI - Lower Extremity Motor Score</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Minimum 0, maximum 50; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Standards for Neurological Classification of SCI - Sensory light touch score</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Minimum 0, maximum 112; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Standards for Neurological Classification of SCI - Sensory pin prick score</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Minimum 0, maximum 112; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Spinal Injury Association Impairment Scale</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Ordinal alphabetical scale. Range A to E. Change in the scale to one of the subsequent letters in the alphabet means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spinal Cord Independence Measure III</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Composite instrument for the assessment of physical independence; minimum 0, maximum 100; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Index for Spinal Cord Injury II</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Score for walking ability; minimum 0, maximum 20; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10m-walk-test</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Time in seconds required for 10 meter walking; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed-up-and go</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Time in seconds needed to raise from a chair, walk a distance of 3 m, turn back and sit down again; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minutes-walk-test</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Walking distance in meters covered in 6 minutes; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Scale 10</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Instrument comprising 10 numeric analogue scales for intensity and qualities of pain; each item ranges from 0-10; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spinal Cord Injury Pain Basic Dataset</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Composite instrument for the assessment of pain locations, type and intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Assessment of muscle tone and resistance to passive motion; minimum 0, maximum 4, higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn spasm frequency scale</measure>
    <time_frame>2 weeks, 3-6 weeks, 3 month, 6month, 1 year post injury</time_frame>
    <description>Patient rated frequency of spasms; minimum 0, maximum 4; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatosensory evoked potentials</measure>
    <time_frame>2 weeks, 3 months</time_frame>
    <description>Tibial nerve and ulnar nerve; response is graded as ranging from 1=abolished to 4=normal response; higher scores mean better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor evoked potentials</measure>
    <time_frame>2 weeks, 3 months</time_frame>
    <description>Anterior tibial muscle, abductor hallucis, abductor digiti minimi; response is graded as ranging from 1=abolished to 4=normal response; higher scores mean better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroneurography</measure>
    <time_frame>2 weeks, 3 months</time_frame>
    <description>Abductor hallucis and abductor digiti minimi; latency, amplitude and F-waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sympathetic skin response</measure>
    <time_frame>2 weeks, 3 months</time_frame>
    <description>Skin response at palm and sole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Leukocyte Antigen - DR isotype expression on monocytes</measure>
    <time_frame>1 day, 3 days, 1week, 2 weeks, 3-6 weeks, 3 months, 6 months, 1 year post injury</time_frame>
    <description>Anti-Human Leukocyte Antigen - DR isotype antibodies bound per monocyte, higher values mean better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune phenotyping</measure>
    <time_frame>1 day, 3 days, 1week, 2 weeks, 3-6 weeks, 3 months, 6 months, 1 year post injury</time_frame>
    <description>Panel of T-lymphocyte and B-lymphocyte subpopulations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional immune assays</measure>
    <time_frame>1 day, 3 days, 1week, 2 weeks, 3-6 weeks, 3 months, 6 months, 1 year post injury</time_frame>
    <description>White blood cell ex-vivo stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Damage Associated Molecular Patterns</measure>
    <time_frame>1week, 3 months,</time_frame>
    <description>Immunoassays in plasma and CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Ferroptosis</measure>
    <time_frame>1week, 3 months</time_frame>
    <description>Immunoassays in plasma and CSF</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Spinal Cord Trauma</condition>
  <arm_group>
    <arm_group_label>Complete SCI, AIS A</arm_group_label>
    <description>Patients with complete spinal cord injury (AIS A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Incomplete SCI, AIS B, C, D</arm_group_label>
    <description>Patients with incomplete spinal cord injury (AIS B, C, D)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vertebral injuries without SCI</arm_group_label>
    <description>Patients with vertebral injuries without spinal cord injury (control)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, peripheral blood mononuclear cells, cerebrospinal fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants from primary care clinics&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute traumatic SCI, American Spinal Injury Association Impairment Scale (AIS) A to D,&#xD;
             neurologic level of injury C3 - L2 or acute vertebral fracture without SCI&#xD;
&#xD;
          -  Inclusion within 21 days post-injury&#xD;
&#xD;
          -  For Italian centers only: SCI-Treatment using Methylprednisolone (according to&#xD;
             NASCIS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-traumatic SCI&#xD;
&#xD;
          -  Severe multiple trauma&#xD;
&#xD;
          -  Serious traumatic brain injury&#xD;
&#xD;
          -  Pre-exiting neurological diseases&#xD;
&#xD;
          -  Malignant Neoplasia, except in complete remission for 5 years&#xD;
&#xD;
          -  Rheumatic diseases / collagenosis / vasculitis&#xD;
&#xD;
          -  Other autoimmune diseases&#xD;
&#xD;
          -  Pre-existing chronic infection&#xD;
&#xD;
          -  Severe alcohol or drug addiction&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Simultaneous participation in interventional clinical trials&#xD;
&#xD;
          -  For centers in Germany or Switzerland only: SCI-treatment using Methylprednisolone&#xD;
             (according to NASCIS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jan M Schwab, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcel A Kopp, MD</last_name>
    <role>Study Director</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcel A Kopp, MD</last_name>
    <phone>+49 30 450560075</phone>
    <email>marcel.kopp@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Blex, PhD</last_name>
    <phone>+49 30 450560075</phone>
    <email>christian.blex@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BG Hospital Unfallkrankenhaus Berlin, Treatment Centre for Spinal Cord Injuries</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Liebscher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Neurorehabilitation, Santa Lucia Foundation</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marcella Masciullo, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Marcel Kopp, MD</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

